Publications + Posters

Preclinical evaluation of the CNS penetration of a novel series of MTA-cooperative PRMT5 inhibitors including TNG456

Alice Tsai, et al.

TNG456 is a next-generation, brain-penetrant, MTAcooperative PRMT5 inhibitor for the treatment of solid tumors including glioblastoma with MTAP loss

Kimberly J. Briggs, et al.

| ACT Annual Meeting

Nonclinical Safety Evaluation of MTA-Cooperative PRMT5 Inhibitors: Implications for Therapeutic Selectivity and Tolerability

Alice Tsai, et al.

| Eastern Analytical Symposium

Development of a control strategy for peroxide in tetrahydrofuran based on a simple method to mitigate the risk of oxidation product formation for Vopimetostat (TNG462)

Zhengyang (Allen) Xin, et al.

A Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TNG260 in combination with pembrolizumab in patients with STK11-mutated advanced solid tumors

Salman R. Punekar, et al.

Learn more about our drug discovery programs and explore our pipeline.

Learn more about our drug discovery programs and explore our pipeline.